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Abstract
The HUGO Committee on Ethics, Law and Society (CELS) undertook a Working Group exploration of the key ethical
issues arising from genome sequencing in 2013. The Imagined Futures paper the group subsequently published
proposed points to consider when applying genomic bioinformatics to data repositories used in genomic medicine
and research (http://www.hugo-international.org/Resources/Documents/CELS_Article-ImaginedFutures_2014.pdf).
Given the ever-increasing power to sequence the human genome rapidly and inexpensively—as well as trends toward
“Big Data” and “Open Science”—we take this opportunity to update and refine the key findings of that paper.
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Introduction
In 2013, the Human Genome Organisation’s (HUGO)
Committee on Ethics, Law and Society (CELS) under-
took a Working Group exploration of the key ethical
issues arising from genome sequencing, focusing on bio-
informatics: an umbrella term linking biological data
with techniques for information storage, access, and ana-
lysis to support multiple areas of scientific research and
clinical treatment.1 The following is a HUGO Statement
based on the Imagined Futures paper the Working
Group published, in which a framework for oversight of
genomic repositories was developed. This Statement
provides an ethical and philosophically consistent basis
to regulate and apply bioinformatics in genomic research
and clinical practice. The Working Group developed the
following principles:2
Social justice: Based on HUGO’s affirmation to “adhere
to international norms of human rights” and HUGO’s
leitmotiv to recognize the “genome as the common
heritage of humanity,” social justice is the right of every in-
dividual to share in the benefits of scientific progress and
its technological applications.3 The strongest statement on
social justice from HUGO can be found in the Statement
on Benefit Sharing (2000):
“At present there is a great inequality between the
rich and poor nations in the direction and priorities of
research and in the distribution and access to the
benefits thereof. When there is a vast difference in
power between those carrying out the research and
the participants, and when there is a possibility of
substantial profit, considerations of justice support the
desirability of distributing some profits to respond to
health care needs.”
Genomic solidarity: HUGO’s first articulation of gen-
omic solidarity also came in its Statement on Benefit
Sharing, which stated:
“The sharing of genes may call for strong solidarity
within certain groups of people. Members of a small
group with rare genes who have helped research
would be particularly deserving recipients of benefits.
… It is in everyone’s best interest that wealthy and
powerful nations as well as commercial entities foster
health for all humanity.”
This principle naturally follows from social justice be-
cause differences between individuals, communities, and
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populations, revealed by genomic research, should not limit
fair opportunities or lead to discrimination. Therefore, gen-
omic research should be a reciprocal exchange between in-
dividuals and communities, with researchers, funders, and
sponsors, so that all participants (human beings as origina-
tors of sequences) share in the benefits of the research
through knowledge dissemination and progress, and not
just as end-product users, for the reason that may create
inequity because of commercial interests and differential
access. Solidarity, however, is reciprocal with the “right to
the protection of the moral and material interests resulting
from any scientific, literary or artistic production of which
[they are] the author.”4 Practicing solidarity thus also in-
volves: upholding quality research as correlative to it being
ethical; establishing scientists’ accountability to funders,
participants, and publics; and societal support for bona fide
scientists in their contributions to the public good.5
“For the public good”:6 All social endeavors—including
genomic research—should benefit individuals as mem-
bers of the community of rights.7 Here, equity involves
working to reduce health inequalities among different
populations by promoting equal access to the benefits of
scientific progress.8 Equity should be a prerequisite for
translating genomic knowledge into socially and morally
valued public goods. In focusing on the public good, we
believe that future regulatory models should be aimed at
generating public social benefit and not merely private
commercial gains.
The Imagined Futures paper
Imagined Futures focused on three “futures” (see the
“Appendix” section):
1. Clinical indications for whole genome sequencing,
2. Cancer genomics in diagnosis and therapeutic
guidance, and
3. Microbial genomics and metagenomics.
For each of these topics, the Working Group systemat-
ically examined how the translation of genome science
could occur in a way that positively “captures” the public
good: conditions for knowledge production, and its ac-
cess and use for morally worthy purposes. We analyzed
which conditions were necessary for the benefits of these
imagined futures to materialize and which potential bar-
riers existed toward those goals.
In all three futures, bioinformatics will have a central
role in creating opportunities for genomics to benefit
society. Such outcomes will depend on appropriate regu-
lation and clinical governance of some complex tasks,
and significantly, the creation and management of data
repositories. While the “imaginaries” are potentially pro-
phetic, the reality of the technical aspects of genome
sequencing is significant. In this respect, the Imagined
Futures paper focused on how bioinformatics, as a tech-
nical consideration of data collection and storage in
large scale repositories, requires consideration of ethical,
legal, and social oversight.
The genomic “revolution” relied on developing power-
ful sequencing technologies and the concomitant ad-
vances of computational capabilities, and it is therefore
important to note the technical limitations and chal-
lenges of bioinformatics:
 Clinical sequences must be accurate and with
very low error rates.
 Even comparatively low-cost whole genome
sequencing could remain too expensive for
common use in health care for countries with
limited resources.
 Specific standards are needed to calibrate
sensitivities and specificities across heterogeneous
technical platforms.
With ever-increasing power to sequence the human
genome rapidly and inexpensively, come challenges asso-
ciated with “Big Data” and “Open Science,” and in these
respects, ethical frameworks for bioinformatics will be
fundamental. While Big Data increases the scale and
ease of analyzing troves of data to reveal patterns, Open
Science changes what is knowable, accessible, and use-
able in terms of making scientific research more socially
just. As both raise questions about the ethical conditions
for data collection and usage, the public good is likely to
play a key role in creating new paradigms for safeguards
and oversight of data collection and storage.
The Statement
Imagining genomic data repositories When patients,
clinicians, and researchers entrust genomic data to a
data repository, they generally want assurances that:
 The information will be available when needed.
 The information is accurate, correct, and validated.
 The information will be shared with others and used
in an appropriate manner.9
We imagine an approach in which a person’s whole
genome is sequenced at one time, and then stored in a
trusted genomic repository. Different designated path-
ways will be “gated” to protect the interests in “clinical,”
“research,” and “public health.” These three pathways
will each require the clarification of specific and shared
ethical and legal conditions. All three will require similar
bioinformatics considerations regarding data intake, data
use, long-term storage, translation, and resolving threats
to the repository (e.g., disasters, human errors, hacking,
and computational attacks, “bit rot,”10 and format
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obsolescence). Therefore, the Imagined Futures model
will generally require that:
 Only complete genome sequences with appropriate
accuracy metrics will be deposited in the data
repository.
 This repository has reasonable and up-to-date priv-
acy and security safeguards.
 The data are stored in a stable format and use
ethically and legally sustainable process of access.
 Indications for new sequencing are clear, with
inevitable technical innovations.
 Depending on the analysis schedule, sequences from
specified regions of the genome will be accessed,
analyzed, and interpreted by professional, skilled
genomic analysts.
Recommendations Recognizing that:
i. Genetic determinism does not reflect the range and
complexity of factors (including genes) that
influence human health and development.
ii. Social justice can promote the public good by
challenging the vagaries of the for-profit sector
in genomic research (i.e., recognizing and
admonishing conflicts of interest).
iii. The complexity of the data gives rise to technical
challenges, as well as problems of its interpretation
both as clinical and biological information.
iv. Practical solutions to these challenges are needed in
order to maximize potential public goods. These
may include technical, professional, educational,
and regulatory approaches.
v. Potential benefits should not be confined to
specific regions of the world, such as those rich
in resources.
vi. The protection of individual and community rights
should be balanced with the broader interests of
society (including the right to benefit from scientific
advancement).11
vii. Regulation can improve public trust in new
technology by letting people know that its
developments and uses are being monitored and
that controls and sanctions are in place to prevent
misuse.
Subject to these Imagined Futures becoming real, the
HUGO Committee on Ethics, Law and Society recom-
mends that:
1. Human genome sequences should be stored in a
safe and long-term professional environment. It
should be retrievable, either in whole or in part,
based on the appropriate scientific and ethical
conditions for research, clinical practice, and public
health:
i. The trusted genomic repository (TGR) as a
whole must be run by a trustworthy entity, i.e.,
a custodian who diligently applies appropriate
policies and reacts appropriately when the
policies are breached;
ii. As part of its data quality control procedures,
the TGR should only accept data from sources
it considers valid and trustworthy;
iii. The TGR must have documented, well-understood
policies stating who is allowed to do what to
which data, for which purpose, and when;
iv. The TGR must have policies regarding how long
data will be retained and when and how they
should be purged;
v. The repository must follow standard best
practices for mitigating known threats and
evolve to address new ones;
vi. Contributors and patients should know how their
genome sequences may be accessed and for what
reasons, and that technical limits to anonymity
mean that some risks will always remain;
vii. There should be a new profession for
computationally enabled genomic analysts or
“genomic bioinformatician.” Accreditation of
that role will set the standards for interpretive
genomic medicine and research.
2. Consideration should be given to the establishment
of a forum for global consensus building related to
TGRs as they develop links to one
another—perhaps under the auspices of HUGO.
3. HUGO should continue to promote international
norms of human rights as the basis for public
health, recognizing that specific regulatory
measures should be kept up to date, and should not
obstruct science or become isolated from the
public’s views on the technologies or applications.
In research applications,
4. Jurisdictions should consider the merits of
establishing consolidated databases for full genome
sequences of human and non-human animals, as
well as relevant plants, bacteria, and viruses, as a
resource for public health.12
5. Regulations should be compatible with best practices
and harmonized with international standards to ensure
that there is no weak link in the regulatory chain.
In clinical applications,
6. Genomic sequencing technologies should be
translated into the medical practice in ways that
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reflect the complementarity of personalized
medicine with the collective benefits of public
health.
7. Terminology and indications for redoing a clinical
sequence are not settled. “Re-sequencing” is starting
a new biochemical assay with a new sample or
DNA from the original sample. “Re-interpretation”
is taking the first sequence but putting it through
new analytic (computer) algorithms or rewriting the
clinical report in view of new literature on the
variants seen. Issues of all new sequencing
chemistries should be raised as well as sequencing
other samples, such as RNA sequencing from actual
diseased tissue (cancer or other).
8. Genome sequencing standards should be
established by professional or national metrology
groups to ensure:
i. The high quality of each individual/’s genome
sequence;
ii. The quality of clinical interpretation for these
data;
iii. That health care professionals have well-defined
obligations and responsibilities as legal owners
or stewards of the genomic data, circumstances
in which the data is provided and collected, and
in respect to the conditions for inclusion in the
data and the patients it pertains to.
We note that the research, clinical, and public health
domains are not mutually distinct.
Concluding remarks
The original Imagined Futures noted that the context of
existing international systems considerably complicates any
singular regulatory model and its effectiveness. Complexity
stems from economic, ethical, legal, and social permuta-
tions; terminological distinctions and boundaries; and
conditions appropriate for various different forms of speci-
mens, information, and code or formula, that may be stored
alongside genomic sequences. Socio-economic and cultural
differences are amplified as regulators transition from local
contexts, through to regions of cohabiting communities,
and finally internationally. This Statement, therefore, is
intentionally broad to recognize challenging regulatory
environments and to focus on areas in which there is
inadequate oversight.13 Advances in science and technology
have become key drivers in international relations; thus,
this Statement may form the basis of these relations and
cooperation with respect to ethical bioinformatics in
genomics. The Statement does not preclude a role for
other international bodies involved in standard setting in
the genomics area; these can be effectively drawn on to
provide further and strengthened cooperation. There are
also a range of international research organizations (e.g.,
International Stem Cell Consortium) that have developed
guidelines in specific fields that, within a particular frater-
nity of professionals, provide harmonized standards for
research and clinical practice. HUGO encourages national
and international regulatory bodies to continue to work
together, such as the recent joint initiatives of the Human
Variome Project and HUGO. Although individual re-
sponses to this Statement will depend on individual coun-
tries, organizations, and initiatives, HUGO believes that
fundamental values must be the same in the achievement
of our imagined future for the public good.
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Appendix
The Imagined Futures
Imagined future 1: clinical indications for whole genome
sequencing
Complete sequence information of an individual can
provide a great deal of clinically useful information
concerning disease risk, treatment response, and risk for
adverse drug effects. These genetic data must be reinter-
preted, even re-sequenced, as new clinical and technical
information arises. Assuming that a sequence will be de-
finitively assayed at least once in life (e.g., at birth), this
scenario imagines when and how health care profes-
sionals will query an individual’s stored sequence.
Imagined future 2: cancer genomics in diagnosis and
treatment
Biomarkers and therapeutic markers already play a major
role in clinical oncology. Our scenario further imagines
that genomics will become routinely employed in the clin-
ical management of cancers and probably other disorders.
Imagined future 3: microbial genomics and metagenomics
Microbial genomics is the sequencing, analysis, interpret-
ation, and application of genomic data from individual
bacterial, viral, and other pathogenic agents. Metage-
nomics is the study of sequence information from micro-
bial communities, including those that colonize human
tissues and organs such as the gut, lungs, skin, and naso-
pharynx. In the third scenario, sequence-based diagnostics
incorporating this information tailors therapeutics for op-
timizing individual patient outcomes, understanding local
epidemiology, and improving community health.
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